^
Association details:
| Biomarker: | PDGFRA exon 18 mutation |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
10/30/2020
Excerpt:
For PDGFRA exon 18 mutations, consider dasatinib (for PDGFRA D842V mutation) or imatinib (for imatinib-sensitive PDGFRA exon 18 mutations).
